<DOC>
	<DOCNO>NCT00676663</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy entinostat combination exemestane treatment advance breast cancer .</brief_summary>
	<brief_title>Study Evaluate Exemestane With Without SNDX-275 Treatment Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Postmenopausal female patient Histologically cytologically confirm ER+ breast cancer Relapsed progressed prior treatment AI Metastatic disease must measurable Patients receive palliative radiation nontarget lesion must 2 week wash period follow completion treatment prior enrollment Patient may one prior chemotherapy part first line therapy long receive initiation prior AI ECOG performance status : 0 1 Laboratory parameter : ) Hemoglobin ≥ 9.0 g/dL ; platelet ≥ 100.0 x 109/L ; ANC ≥ 1.5 x 109/L without use hematopoietic growth factor b ) Creatinine le 2.5 time upper limit normal institution c ) AST ALT less 2.5 time upper limit normal institution Able understand give write informed consent comply study procedure Relapse treatment nonsteroidal AI le 12 month patient adjuvant set Progressive disease le 3 month treatment recent AI patient metastatic disease Rapidly progressive , lifethreatening metastasis Any palliative radiotherapy measurable lesion Previous treatment SNDX275 HDAC inhibitor include valproic acid Allergy benzamides inactive component study drug A history allergy active inactive ingredient exemestane Any concomitant medical condition precludes adequate study treatment compliance Patient currently enrol ( complete within 30 day study drug administration ) another investigational drug study Patient currently receive treatment valproic acid , Zolinza ( vorinostat ) HDAC inhibitor DNA methyltransferase inhibitor systemic anticancer treatment ( exception Lupron )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Breast Tumor</keyword>
	<keyword>Mammary Neoplasms</keyword>
</DOC>